Expertise in
11
conditions

Lillian L. Siu

Toronto, ON, CA 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
11
conditions
Toronto, ON, CA 

Overview

Lillian Siu practices practicing medicine in Toronto, Canada.

Ms. Siu is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Head and Neck Squamous Cell Carcinoma (HNSCC), Salivary Gland Tumors, Nasopharyngeal Carcinoma, and Colorectal Cancer.

She is actively involved in clinical research, co-authoring 294 peer reviewed articles and participating in 19 clinical trials.

Gender

Female

Locations

Toronto, ON, Canada
Other Locations
Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

A Phase 1 Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
A Phase 1 Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: July 22, 2026
Intervention Type: Drug
Study Drug: SGN-PDL1V
Study Phase: Phase 1
Canadian Atezolizumab Precision Targeting for Immunotherapy Intervention
Canadian Atezolizumab Precision Targeting for Immunotherapy Intervention
Enrollment Status: Recruiting
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic Therapies
Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic Therapies
Enrollment Status: Completed
Publish Date: July 14, 2026
A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies
A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 1
Investigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation
Investigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation
Enrollment Status: Active_not_recruiting
Publish Date: June 08, 2026
Intervention Type: Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase 1 First-Time-in-Human, Open-Label Study of GSK6097608 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
A Phase 1 First-Time-in-Human, Open-Label Study of GSK6097608 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: October 27, 2025
Intervention Type: Drug
Study Phase: Phase 1
An Open-Label, Phase III Study of Platinum-Gemcitabine With or Without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
An Open-Label, Phase III Study of Platinum-Gemcitabine With or Without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Enrollment Status: Terminated
Publish Date: October 03, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Carboplatin, Cisplatin, Gemcitabine, Nivolumab
Study Phase: Phase 3
Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy
Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2025
Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects With Advanced Solid Tumors or Lymphomas
Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects With Advanced Solid Tumors or Lymphomas
Enrollment Status: Completed
Publish Date: April 02, 2025
Intervention Type: Drug
Study Drug: SL-279252
Study Phase: Phase 1
A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma
A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma
Enrollment Status: Completed
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drugs: GSK3326595, Pembrolizumab
Study Phase: Phase 1
View 8 Less Clinical Trials

294 Total Publications

Metastatic patterns, outcomes, and prognostic factors in de novo metastatic head and neck cancer by tumor HPV status.
Metastatic patterns, outcomes, and prognostic factors in de novo metastatic head and neck cancer by tumor HPV status.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: June 16, 2026

Frequently Asked Questions about Lillian L. Siu

Is Lillian L. Siu a top-rated expert for Head and Neck Squamous Cell Carcinoma (HNSCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Lillian L. Siu is classified as an Elite expert for Head and Neck Squamous Cell Carcinoma (HNSCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Lillian L. Siu participate in research or clinical trials?

Yes. Lillian L. Siu has published 294 articles and abstracts on conditions like Head and Neck Squamous Cell Carcinoma (HNSCC). You can view a list of Lillian L. Siu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Siu's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 26 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile